Original air date:
Sunday, August 1, 2021
Running time: 15 minutes
Alex Abitbol, MD; Jill Trinacty, MD
In this episode, we are joined by Alex Abitbol, Endocrinologist and assistant medical director at LMC Healthcare and Jill Trinacty, Endocrinologist at LMC Healthcare, Bariatric Medical Institute and Wharton Medical Clinic. In their discussion around the use of GLP-1RAs, they challenge old paradigms in favour of earlier utilization based on proven benefits such as preventing major cardiovascular outcomes. What are the important distinctions in primary and secondary cardiovascular risk prevention with antihyperglycemic therapy? Listen to find out.
The views information and opinions expressed in this podcast are solely those of the individuals involved and do not represent those of Novo Nordisk.
This podcast does not constitute medical advice and is only meant to educate and inform the listener.
This podcast has been supported by educational funding from Novo Nordisk.